Abstract
Background
Chronic obstructive pulmonary disease (COPD) is a common disease that can be prevented and even treated. It leads to high morbidity and mortality rates. Pro-inflammatory cytokines and oxidative radicals were found to be implicated in COPD pathogenesis.
Objectives
To measure serum level of interleukin 6 (IL-6) in patients with stable COPD and also to detect the relationship of IL-6 levels with COPD severity.
Patients and methods
A total of 50 patients having stable COPD, in addition to 20 healthy control individuals, were included in the study. History taking and clinical examination, BMI calculation, spirometry (postbronchodilator spirometry in COPD group), and 6-min walk test were done for all patients. Measurement of serum level of IL-6 was done by using the enzyme-linked immunosorbent assay.
Results
Serum level of IL-6 showed significantly higher concentrations among patients with COPD compared with healthy individuals [359.87±106.99 and 188.92±77.97 pg/ml, respectively; P<0.001]. An inverse nonsignificant correlation was found between serum level of IL-6 and 6-min walk test distance, forced expiratory volume in the 1 s, forced vital capacity, and maximum expiratory flow 25–75% predicted values. Mean IL-6 level was higher in the patients with severe and very severe COPD (371.75±103.12 pg/ml) compared with those with mild and moderate COPD (336.82±113.72 pg/ ml) (P=0.291).
Conclusion
Serum level of IL-6 showed significant higher concentrations in patients with COPD when compared with control ones, but IL-6 level did not show significant correlation with the disease severity.
Article PDF
Similar content being viewed by others
References
Wang C, Xu J, Yang L, Xu Y, Zhang X, Bai C, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet 2018; 391:1706–1717.
Balkissoon R, Lommatzsch S, Carolan B, Make B. Chronic obstructive pulmonary disease: a concise review. Med Clin 2011; 95:1125–1141.
Hillas G, Perlikos F, Tsiligianni I, Tzanakis N. Managing comorbidities in COPD. Int J Chron Obstruct Pulmon Dis 2015; 10:95.
Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am J Med 2003; 114:758–762.
Jones RL, Noble PB, Elliot JG, James AL. Airway remodelling in COPD: it’s not asthma!. Respirology 2016; 21:1347–1356.
Zeng YY, Hu WP, Zuo YH, Wang XR, Zhang J. Altered serum levels of type I collagen turnover indicators accompanied by IL-6 and IL-8 release in stable COPD. Int J Chron Obstruct Pulmon Dis 2019; 14:163.
Franciosi LG, Page CP, Celli BR, Cazzola M, Walker MJ, Danhof M, et al. Markers of disease severity in chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2006; 19:189–199.
Garcia-Rio F, Miravitlles M, Soriano JB, Muñoz L, Duran-Tauleria E, Sánchez G, et al. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir Res 2012; 11:1–15.
Wedzicha JA, Seemungal TAR, MacCallum PK, Paul EA, Donaldson GC, Bhowmik A, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000; 84:210–215.
Ancochea J, Badiola C, Duran-Tauleria E, Río FG, Miravitlles M, Muñoz L, et al. The EPI-SCAN survey to assess the prevalence of chronic obstructive pulmonary disease in Spanish 40-to-80-year-olds: protocol summary. Arch Bronconeumol (English Ed) 2009; 45:41–47.
Pinto-Plata V, Casanova C, Müllerova H, de Torres JP, Corado H, Varo N, et al. Inflammatory and repair serum biomarker pattern. Association to clinical outcomes in COPD. Respir Res [Internet] 2012; 13:71.
Akbulut HH, Ozden M, Deveci F, Muz MH. IL-6 and IL-8 levels in patients with acute exacerbation of chronic obstructive pulmonary disease. J Clin Diagn Res 2009; 3:1285–1288.
Agusti AGN, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003; 21:347–360.
Rincon M, Irvin CG. Role of IL-6 in asthma and other inflammatory pulmonary diseases. Int J Biol Sci 2012; 8:1281–1290.
Agustí A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012; 7:e37483.
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease. 2016.
Chan YH. Biostatistics102: quantitative data – parametric & non-parametric tests. Singapore Med J 2003a; 44:391–396.
Chan YH. Biostatistics 103: qualitative data –tests of independence. Singapore Med J 2003b; 44:498–503.
Chan YH. Biostatistics 104: correlational analysis. Singapore Med J 2003c; 44:614–619.
Wei J, Xiong X, Lin Y, Zheng B, Cheng D. Association between serum interleukin-6 concentrations and chronic obstructive pulmonary disease: a systematic review and meta-analysis. Peer J 2015; 3:e1199.
El-Shimy WS, El-Dib AS, Nagy HM, Sabry W. A study of IL-6, IL-8, and TNF-α as inflammatory markers in COPD patients. Egypt J Bronchol 2014; 8:91.
de Moraes MR, da Costa AC, de Sousa Corrêa K, Junqueira-Kipnis AP, Rabahi MF. Interleukin-6 and interleukin-8 blood levels’ poor association with the severity and clinical profile of ex-smokers with COPD. Int J Chron Obstruct Pulmon Dis 2014; 9:735.
Kolsum U, Roy K, Starkey C, Borrill Z, Truman N, Vestbo J, et al. The repeatability of interleukin-6, tumor necrosis factor-α, and C-reactive protein in COPD patients over one year. Int J Chron Obstruct Pulmon Dis 2009; 4:149.
Soler N, Ewig S, Torres A, Filella X, Gonzalez J, Zaubet A. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J 1999; 14:1015–1022.
Samy N, El-Maksoud A, Khayyal AE, Imam A. Clinical utility of biomarkers as predictors of lung function in chronic obstructive pulmonary disease. NY Sci J 2010; 3:25–32.
Attaran D, Lari SM, Towhidi M, Marallu HG, Ayatollahi H, Khajehdaluee M, et al. Interleukin-6 and airflow limitation in chemical warfare patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2010; 5:335.
Author information
Authors and Affiliations
Corresponding author
Additional information
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Abd Elnaby, E.A., Abd Elnaiem, S.S., Mostafa, A.I. et al. Assessment of serum interleukin 6 level in patients with chronic obstructive pulmonary disease: is it related to disease severity?. Egypt J Bronchol 13, 575–579 (2019). https://doi.org/10.4103/ejb.ejb_50_19
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.4103/ejb.ejb_50_19